Trials Sponsors Conditions Drugs Pricing

Conditions

Disease Related Malnutrition

Outcome Measures

Primary Outcomes (3)

Acceptability and Palatability of Oral Nutrition Supplement
To assess the acceptability of the shot-style protein supplement in patients requiring oral nutritional supplementation. On day 7 and 28 of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new oral nutrition supplement. A 5 point hedonic scale will be used.
28 days
Gastro-Intestinal (GI) Tolerance
To assess the GI tolerance of the shot-style protein supplement in patients with or at risk of disease related malnutrition, requiring additional protein, either fed orally or with a feeding tube. Monitoring includes recording the number of any GI complaints and consistency of bowel movements via a diary for the first 7 days
7 days
Compliance
To assess the compliance of patients taking the Study product as prescribed. This is measured by daily completion of a compliance diary, comparing consumed amount versus prescribed amount.
28 days

Secondary Outcomes (1)

Safety of consumption of Study Product
7 days

Study Arms (1)

Shot style protein supplement

EXPERIMENTAL

Patients with or at risk of DRM, who have been clinical identified as requiring additional protein will be prescribed the study product for a period of 7-28days. Study product can be taken either orally or via a feeding tube.

Dietary Supplement: Shot Style protein supplement

Interventions

Shot Style protein supplementDietary supplement

The Study product is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.

Shot style protein supplement

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Adult patients (≥18 years) who are able to communicate clearly.
Diagnosis of renal disease or confirmed requirement for protein supplementation by a suitably qualified health care professional (e.g. dietitian)

Sponsors & Collaborators

Aymes International Limited
Industrylead

Study Sites (1)

UCLH NHS Foundation Trust

London, NW1 2PG, United Kingdom

RECRUITING

James Evans, DieteticsCONTACT0044 0203 447 9289 j.evans28@nhs.net

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NA
Masking: NONE
Purpose: OTHER
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

February 11, 2026

First Posted

February 18, 2026

Study Start

September 30, 2022

Actual (reported)

Primary Completion

April 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Tolerance and Acceptability Evaluation of an Oral Nutrition Supplement

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

Shot style protein supplement

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (3)

Secondary Outcomes (1)

Study Arms (1)

Shot style protein supplement

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations